JCR Pharmaceuticals Co., Ltd. (TYO: 4552)

Market Cap	71.27B
Revenue (ttm)	35.26B
Net Income (ttm)	-437.00M
Shares Out	121.82M
EPS (ttm)	-3.50
PE Ratio	n/a
Forward PE	16.64
Dividend	20.00 (3.38%)
Ex-Dividend Date	Mar 28, 2025

Volume	270,600
Open	591.00
Previous Close	592.00
Day's Range	580.00 - 591.00
52-Week Range	466.00 - 1,228.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jan 31, 2025

About JCR Pharmaceuticals

JCR Pharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The comp...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1975
• Employees: 934
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4552

Financial Performance

In 2023, JCR Pharmaceuticals's revenue was 42.87 billion, an increase of 24.83% compared to the previous year's 34.34 billion. Earnings were 5.51 billion, an increase of 46.00%.